J07BN01 - Covid-19, RNA-Based Vaccine |
Propably not porphyrinogenic |
PNP |
Rationale
Based on the pharmacokinetics of the RNA-based covid-19 vaccine, no porphyrinogenic effects are expected.
Chemical description
mRNA-based vaccine.
Therapeutic characteristics
Indicated for preventing coronavirus disease 2019 (COVID-19) in individuals from the age of 6 months. It is administered by intramuscular injections.
Metabolism and pharmacokinetics
Vaccines are not metabolized by the cytochrome P450 system.
Similar drugs
References
| # | Citation details | PMID |
|---|---|---|
| * | Government bodies | |
| 1. | European Medicines Agency (EMA). SmPC Comirnaty.
|
|
| 2. | Norwegian institute of public health. Vaccines and vaccination.
|
|
Tradenames
Comirnaty · Kostaive COVID · Spikevax 
Comirnaty · Kostaive · Spikevax 
Comirnaty · Spikevax 
Comirnaty · Kostaive · Spikevax 
Comirnaty 
Comirnaty 
Comirnaty · Spikevax 
Comirnaty · Spikevax 
Comirnaty · Kostaive · Spikevax 
Comirnaty · Spikevax 
Comirnaty · Spikevax 
Comirnaty · Spikevax 
Comirnaty · Spikevax 
Comirnaty · Kostaive · Spikevax 
Comirnaty · Kostaive · Spikevax 
Comirnaty · Spikevax 
Comirnaty 
Comirnaty · Spikevax 
Comirnaty · Spikevax 
Vaccines